WHO EB 146 Agenda Item 8: Global vaccine action plan
Geneva, 6 February, 2020: IFPMA welcomes a renewed immunization strategy, supporting Heads of States’ commitment to “accelerate efforts towards the achievement of UHC by 2030 to ensure healthy lives and promote well-being for all throughout the life-course”.
IFPMA supports SAGE recommendations, in particular integration between disease-elimination initiatives and national immunization programs as achieved in “Defeating Meningitis 2030”. The main action to prevent and control epidemic is achieving higher coverage of existing vaccines globally and improved prevention strategies.
We are disappointed that more coherence among global strategies did not materialize to maximize the impact of immunization. The recommendations of the IACG on AMR to strengthen national systems for vaccinations and reduce the need for antimicrobials should be addressed with the integration of the WHO roadmap of priority actions for vaccines and AMR in the post-2020 immunization strategy.
Finally, there is an opportunity to significantly strengthen the imperative that government invest more, better, and efficiently in immunization programs to improve infection prevention and control, by setting appropriate national financing targets for quality investments, which minimize out-of-pocket payments by patients and healthy people. An immunized population can drive economic growth, development, and wealth.
The post-2020 immunization strategy offers a unique chance to consider policy changes needed to concretely improve population health and promote health system sustainability through increasing vaccination coverage across the life-course. We look forward to strengthen our constructive collaboration with the WHO.
About IFPMA
IFPMA represents the innovative pharmaceutical industry at the international level, engaging in official relations with the United Nations and multilateral organizations. Our vision is to ensure that scientific progress translates into the next generation of medicines and vaccines that deliver a healthier future for people everywhere.
ifpma.org
To achieve this, we act as a trusted partner, bringing our members' expertise to champion pharmaceutical innovation, drive policy that supports the research, development, and delivery of health technologies, and create sustainable solutions that advance global health.
Related news and resources
The value of prevention for economic growth and the sustainability of healthcare, social care and welfare systems (The European House – Ambrosetti)
Over the last decade, the EU economy has experienced slow growth, and it is not expected to grow substantially in the coming years. Additionally, the ongoing demographic and epidemiological transition is increasing pressure on public finances, particularly healthcare and social expenditure. The current permacrisis – encompassing geopolitical and climate-related challenges – exacerbates these issues and...
Read more
Only an urgent shift towards prevention-based healthcare can secure economic stability for EU health systems, experts say
As Governments of EU Member States present their medium-term fiscal structural plans on 20 September, a new report developed by The European House – Ambrosetti, supported by IFPMA and Vaccines Europe, notes that embedding preventative healthcare – in particular immunisation – into EU Member States’ fiscal policies is paramount to ensure the economic sustainability of...
Read morePharmaceutical industry welcomes the launch of Gavi’s new investment round and AVMA
On 20 June in Paris, Gavi, the Vaccine Alliance, the Government of France and the African Union – together with Team Europe partners, co-hosted The Global Forum for Vaccine Sovereignty and Innovation.
Read more